[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-VQ-Bu1YmInqhiX-J2f0T9-nkM31kxytHE-5VKeGlrQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"Hôpital le Vinatier",[4],102,false,36,1,14759,98,[13,16,19,22,25,28,30,32],{"name":14,"count":15},"Schizophrenia",26,{"name":17,"count":18},"Autism Spectrum Disorder",8,{"name":20,"count":21},"Depression",4,{"name":23,"count":24},"22q11.2 Deletion Syndrome",3,{"name":26,"count":27},"Transcranial Direct Current Stimulation",2,{"name":29,"count":27},"Addiction",{"name":31,"count":27},"Mental Disorders",{"name":33,"count":27},"Psychiatric Disorder",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05159830","Cannabidiol for Reducing Drinking in Alcohol Use Disorder","2026-09-30","Cannabidiol oral oil",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,72,98,124],{"intervention":39,"totalTrials":9,"cells":49},{"EARLY_PHASE1":50,"PHASE1":53,"PHASE2":55,"PHASE3":66,"PHASE4":68,"NA":70},{"trials":51,"activeCount":52},[],0,{"trials":54,"activeCount":52},[],{"trials":56,"activeCount":9,"soonestReadout":38},[57],{"nctId":36,"briefTitle":37,"status":58,"phases":59,"primaryCompletion":38,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"RECRUITING",[43],"2026-12-31","2024-10-25",76,[64],"Alcohol Use Disorder",[39],{"trials":67,"activeCount":52},[],{"trials":69,"activeCount":52},[],{"trials":71,"activeCount":52},[],{"intervention":73,"totalTrials":9,"cells":74},"Molecular analyses",{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":85},{"trials":76,"activeCount":52},[],{"trials":78,"activeCount":52},[],{"trials":80,"activeCount":52},[],{"trials":82,"activeCount":52},[],{"trials":84,"activeCount":52},[],{"trials":86,"activeCount":52},[87],{"nctId":88,"briefTitle":89,"status":90,"phases":91,"primaryCompletion":92,"completion":93,"start":94,"enrollment":27,"conditions":95,"interventions":97},"NCT04141540","Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11","COMPLETED",[46],"2020-11-30","2020-12-30","2020-03-27",[96],"Di George Syndrome",[73],{"intervention":99,"totalTrials":9,"cells":100},"Hourly dosing of the nychtemeral secretion of melatonin",{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":111},{"trials":102,"activeCount":52},[],{"trials":104,"activeCount":52},[],{"trials":106,"activeCount":52},[],{"trials":108,"activeCount":52},[],{"trials":110,"activeCount":52},[],{"trials":112,"activeCount":52},[113],{"nctId":114,"briefTitle":115,"status":90,"phases":116,"primaryCompletion":117,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},"NCT03492970","Melatonin in Adults With SMS",[46],"2019-01-30","2019-03-30","2018-03-07",10,[122],"Smith Magenis Syndrome",[99],{"intervention":125,"totalTrials":9,"cells":126},"Array comparative genomic hybridization",{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":137},{"trials":128,"activeCount":52},[],{"trials":130,"activeCount":52},[],{"trials":132,"activeCount":52},[],{"trials":134,"activeCount":52},[],{"trials":136,"activeCount":52},[],{"trials":138,"activeCount":52},[139],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT02746510","Validation of a Clinical Screening Grid for Syndromic Schizophrenia","TERMINATED",[46],"2023-02","2023-12-20","2016-07",129,[14],[125]]